Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective

Statistical Methods in Medical Research

Volumn 17, Issue 5, 2008, Pages 497-504

  Alonso, Ariel ^a   Molenberghs, Geert ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COLON CANCER; CONCEPTUAL FRAMEWORK; CONFERENCE PAPER; CONFIDENCE INTERVAL; EARLY CANCER; HUMAN; INDIVIDUALIZATION; INFORMATION SCIENCE; MATHEMATICAL COMPUTING; MAXIMUM LIKELIHOOD METHOD; METHODOLOGY; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; TIME; VALIDATION STUDY;

BIOLOGICAL MARKERS; HUMANS; META-ANALYSIS AS TOPIC; MODELS, THEORETICAL; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 52649180045     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1177/0962280207081851     Document Type: Conference Paper

References (21)

1. Nyquist H. Certain factors affecting telegraph speed. Bell System Technical Journal 1924; 3: 324-46.
2. Hartley R. Transmission of information. Bell System Technical Journal 1928; 7: 535-63.
3. Shannon C. A mathematical theory of communication. Bell System Technical Journal 1948; 27: 379-423, 623-56.
4. Fisher R. Theory of statistical estimation. Proceedings of the Cambridge Philosophical Society 1925; 22: 700-25.
5. Kullback S., Leibler R. On information and sufficiency. Annals of Mathematical Statistics 1951; 22: 79-86.
6. Alonso A., Geys H., Molenberghs G. A unifying approach for surrogate marker validation based on Prentice's criteria. Statistics in Medicine 2006; 25: 205-21.
7. Prentice R. Surrogate endpoints in clinical trials: Definitions and operational criteria. Statistics in Medicine 1989; 8: 431-40.
8. Freedman L., Graubard B., Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11: 167-78.
9. Buyse M., Molenberghs G. The validation of surrogate endpoints in randomized experiments. Biometrices 1998; 54: 1014-29.
10. Albert A., Ioannidis JPA, Reichelderfer P., Conway B., Coombs RW, Crane L., Demasi R., Dixon DO, Flandre P., Hughes MD, Kalish LA, Larntz K., Lin D., Marschner IC, Munoz A., Murray J., Neaton J., Pettinelli C., Rida W., Taylor JMG, Welles SL Statistical issues for HIV surrogate endpoints: Point/counterpoint. Statistics in Medicine 1998; 17: 2435-62.
11. Daniels MJ, Hughes MD Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16: 1515-27.
12. Gail M., Pfeiffer R., Van Houwelingen H., Carroll R. On meta-analytic assessment of surrogate outcomes. Biostatistics 2000; 1: 231-46.
13. Buyse M., Molenberghs G., Burzykowski T., Renard D., Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1: 49-67.
14. Renard D., Geys H., Molenberghs G., Burzykowski T., Buyse M. Validation of surrogate endpoints in randomized trials with discrete outcomes. Biometrical Journal 2002; 44: 1-15.
15. Renard D., Geys H., Molenberghs G., Burzykowski T., Buyse M., Vangeneugden T., Bijnens L. Validation of longitudinally measured surrogate marker for a time-to-event endpoint. Journal of Applied Statistics 2003; 30: 235-47.
16. Alonso A., Molenberghs G. Surrogate marker evaluation from an information theory perspective. Biometrics 2007; 63: 180-186.
17. Burzykowski T., Molenberghs G., Buyse M. The evaluation of surrogate endpoints. Springer, 2005.
18. Sargent DJ, Wieand S., Haller DG, Gray R., Benedetti J., Buyse M., Labianca R., Seitz JF, Callaghan CJO, Francini G., Grothey A., O'Connell M., Catalano PJ, Blanke CD, Kerr D., Green E., Wolmark N., Andre T., Goldberg RM, De Gramont A. Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology 2005; 34: 8664-70.
19. Meta-Analysis Group In Cancer (MAGIC). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. Journal of Clinical Oncology 2004; 22: 3766-75.
20. Alonso A., Molenberghs G., Burzykowski T., Renard D., Geys H., Shkedy Z., Tibaldi F., Abrahantes J., Buyse M. Prentice's approach and the meta analytic paradigm: A reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 2004; 60: 724-28.
21. Sargent DJ, Wieand HJ, Haller DG, Gray R., et al. Disease-free survival versus overall survival as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trails. Journal of Clinical Oncology, 23: 2005; 8664-8670.